-
Sample size efficiency of restricting participation in tuberculosis vaccine trials to interferon-gamma release assay-positive participants
Cobelens, F., Pelzer, P. T., Churchyard, G. J., Garcia-Basteiro, A., Hatherill, M., Hill, P. C., Martinez, L. & White, R. G., 13 Aug 2025, In: Vaccine. 61, 127301.Research output: Contribution to journal › Article › Academic › peer-review
-
Epidemiological insights to inform the development and implementation of new vaccines against tuberculosis
Pelzer, P. T., 2025, 199 p.Research output: PhD thesis › Research HvA, graduation HvA (not in use)
-
Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials
White, R. G., Churchyard, G. J., Horton, K. C., Fiore-Gartland, A., Behr, M. A., Clark, R. A., Cobelens, F., Ernst, J. D., Esmail, H., Garcia-Basteiro, A. L., Hadinegoro, S. R., Hanekom, W. A., Hatherill, M., Hill, P. C., Muloiwa, R., Pelzer, P. T., Rangaka, L., Rees, H., Schrager, L. & Stanley, M. & 3 others, , 2025, (E-pub ahead of print) In: The Lancet Respiratory Medicine.Research output: Contribution to journal › Review article › Academic › peer-review
- All publications
